Biotech Values

[rstor1]

AVGN

+++Touting a lead molecule whose identity hasn’t yet been disclosed strikes me as an act of desperation. Investors need to have more than the usual modicum of trust to buy into a scheme like this.+++

The fact that their IP is close to zero after adding in the GENZ cash makes the downside quite limited. They also have a couple of other programs.

At any rate, they will be disclosing it this quarter.

Regards,
Bob